Beta Bionics, Inc. BBNX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 32.01M | 27.63M | 32.12M | 27.25M | 23.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.01M | 27.63M | 32.12M | 27.25M | 23.24M |
| Cost of Revenue | 13.11M | 11.19M | 13.18M | 12.13M | 10.74M |
| Gross Profit | 18.90M | 16.44M | 18.94M | 15.12M | 12.50M |
| SG&A Expenses | 34.24M | 30.35M | 24.94M | 23.97M | 23.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.59M | 51.90M | 48.25M | 44.30M | 43.11M |
| Operating Income | -25.58M | -24.27M | -16.12M | -17.04M | -19.87M |
| Income Before Tax | -23.40M | -21.90M | -13.47M | -14.21M | -16.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.40M | -21.90M | -13.47M | -14.21M | -16.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.40M | -21.90M | -13.47M | -14.21M | -16.87M |
| EBIT | -25.58M | -24.27M | -16.12M | -17.04M | -19.87M |
| EBITDA | -24.87M | -23.69M | -15.59M | -16.66M | -19.53M |
| EPS Basic | -0.53 | -0.49 | -0.30 | -0.33 | -0.39 |
| Normalized Basic EPS | -0.33 | -0.31 | -0.19 | -0.20 | -0.24 |
| EPS Diluted | -0.53 | -0.49 | -0.30 | -0.33 | -0.39 |
| Normalized Diluted EPS | -0.33 | -0.31 | -0.19 | -0.20 | -0.24 |
| Average Basic Shares Outstanding | 44.55M | 44.44M | 44.19M | 43.63M | 43.39M |
| Average Diluted Shares Outstanding | 44.55M | 44.44M | 44.19M | 43.63M | 43.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |